Lipid accumulation is ahead of epithelial-to-mesenchymal transition and therapeutic intervention by acetyl-CoA carboxylase 2 silence in diabetic nephropathy

Metabolism. 2014 May;63(5):716-26. doi: 10.1016/j.metabol.2014.02.010. Epub 2014 Feb 27.

Abstract

Objective: The study investigated the relationship between epithelial-to-mesenchymal transition (EMT) and lipotoxicity in diabetic nephropathy as well as the protective effect of acetyl-CoA carboxylase 2 (ACC2) silence.

Methods: High glucose (30mmol/L) cultured human proximal tubular epithelial cells (HK-2 cells) were used. Triglyceride content, fatty acid β-oxidation rate, malonyl CoA content, and marker proteins of EMT, including E-cadherin (E-cad), α-smooth muscle actin (α-SMA) and transforming grow factor-β (TGF-β), were assessed. Silence of ACC2 was achieved by ACC2-shRNA lentivirus transfection.

Results: In cultured human proximal tubular cells, high glucose induced fatty acid deposit before phenotypical and morphological changes of EMT. At 48h, more triglyceride content, more malonyl CoA content and lower fatty acid β-oxidation rate were detected. However, increased expression of TGF-β, accompanied by loss of E-cad and acquisition of α-SMA, was observed at 98h but not at 48h. The silence of ACC2 in HK-2 cells led to restored cell morphology with less lipid deposition and less malonyl-CoA content, which resulted from faster β-oxidation rate.

Conclusion: The progress of lipotoxicity participates in the development of diabetic nephropathy in early stage before EMT. The manipulation of lipid metabolism might act as a promising therapeutic intervention for diabetic nephropathy.

Keywords: Diabetes; Epithelial to mesenchymal transition; Lipotoxicity; Proximal tubular epithelial cells; β-oxidation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetyl-CoA Carboxylase / genetics*
  • Cells, Cultured
  • Cytoprotection / drug effects
  • Cytoprotection / genetics
  • Diabetic Nephropathies / genetics*
  • Diabetic Nephropathies / therapy*
  • Epithelial-Mesenchymal Transition* / genetics
  • Fatty Acids / adverse effects
  • Fatty Acids / metabolism
  • Gene Silencing / physiology*
  • Genetic Therapy / methods*
  • Glucose / adverse effects
  • Glucose / pharmacology
  • Humans
  • Lipid Metabolism / physiology*
  • Malonyl Coenzyme A / metabolism
  • Triglycerides / adverse effects
  • Triglycerides / metabolism

Substances

  • Fatty Acids
  • Triglycerides
  • Malonyl Coenzyme A
  • ACACB protein, human
  • Acetyl-CoA Carboxylase
  • Glucose